Ultragenyx to sell rare pediatric disease priority review voucher for $203 million
Bitget2026/10/14 12:32- Ultragenyx signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 203 million.
- The voucher was awarded on FDA clearance of FAYUVI (UX111) for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.
- Closing remains subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays (BCS.US) bets on a merger between Tesla (TSLA.US) and SpaceX (SPCX.US) in December, but prediction markets give only a 19% probability.
Barclays analyst Levy predicts that Tesla and SpaceX may merge before December to achieve AI integration. However, data from Kalshi and Polymarket indicate that the probability of a short-term merger is very low, with the market favoring such a move after 2027.
Barclays (BCS.US) bearish on Dell (DELL.US): No inflection point in AI spending, memory costs are the main reason
Barclays has downgraded Dell from Overweight to Neutral and lowered the target price. The institution noted that corporate AI spending remains low and revenue growth is driven by memory shortages, which stands in stark contrast to Michael Dell’s optimistic outlook.
Crypto prices
More
